Mitomycin-induced hemolytic-uremic syndrome.
Four patients who took the antitumor agent mitomycin manifested microangiopathic hemolytic anemia, thrombocytopenia, and renal failure. At autopsy, kidneys from all four patients had a microangiopathy typical of the hemolytic-uremic syndrome (HUS), with thromboses in glomerular capillaries and arterioles, fibrin deposition in mesangium, and prominent cellular intimal proliferation of the interlobular arteries. Development of the HUS was an important factor contributing to death in all four patients. From a review of the literature and our initial results of a randomized chemotherapy protocol for metastatic adenocarcinoma of the colorectum, it appears that mitomycin was the most likely cause for the development of the HUS in these patients. As more patients are being treated with mitomycin, particular care must be taken to monitor them for development of a drug-induced HUS.
D001158:Arteries / Q000473:pathology; D001344:Autopsy; D002196:Capillaries / Q000473:pathology; D005337:Fibrin / Q000032:analysis; D005920:Glomerular Mesangium / Q000032:analysis / Q000473:pathology; D006463:Hemolytic-Uremic Syndrome / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D007668:Kidney / Q000473:pathology; D007678:Kidney Glomerulus / Q000098:blood supply / Q000473:pathology; D008297:Male; D008937:Mitomycins / Q000009:adverse effects*; D013194:Staining and Labeling
D008937:Mitomycins; D005337:Fibrin